{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:25:44Z","timestamp":1793831144599,"version":"4.6.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EU grant OP VVV","award":["Nr. CZ.02.1.01\/0.0\/0.0\/16_026\/0008388"],"award-info":[{"award-number":["Nr. CZ.02.1.01\/0.0\/0.0\/16_026\/0008388"]}]},{"name":"Charles University, Prague","award":["UNCE MED 02, PROGRESS Q38"],"award-info":[{"award-number":["UNCE MED 02, PROGRESS Q38"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Magnesium-based bioresorbable Magmaris stents are rapidly resorbed. Few randomized studies have evaluated the efficacy of such stents in patients with acute coronary syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To investigate late lumen loss as assessed via quantitative coronary angiography (QCA) and optical coherence tomography (OCT) in patients with acute coronary syndrome treated with Magmaris stents or permanent, everolimus-eluting metallic Xience stents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and Results<\/jats:title>\n                <jats:p>This PRAGUE-22 study was a two-centre, investigator-initiated, randomized study. Fifty patients were randomized based on the inclusion criteria for acute coronary syndrome and the anatomical suitability to receive Magmaris or Xience stents. The patient characteristics did not differ between the Magmaris group (<jats:italic>n<\/jats:italic>\u2009=\u200925) and Xience group (<jats:italic>n<\/jats:italic>\u2009=\u200925). The mean ages were 57.0\u2009\u00b1\u200910.5 vs. 55.5\u2009\u00b1\u20099.2\u00a0years (<jats:italic>p<\/jats:italic>\u2009=\u20090.541) and the total implanted stent length was 24.6\u2009\u00b1\u200910.7\u00a0mm vs. 27.6\u2009\u00b1\u200911.1\u00a0mm (<jats:italic>p<\/jats:italic>\u2009=\u20090.368), respectively. Four clinical events occurred in the Magmaris group and one in the Xience group during 12\u00a0months of follow-up. The extent of late lumen loss (assessed via QCA) at 12\u00a0months was greater in the Magmaris group than in the Xience group (0.54\u2009\u00b1\u20090.70 vs. 0.11\u2009\u00b1\u20090.37\u00a0mm; <jats:italic>p<\/jats:italic>\u2009=\u20090.029). The late lumen loss diameter (measured via OCT) in the Magmaris group was also significantly larger than that in the Xience group (0.59\u2009\u00b1\u20090.37 vs. 0.22\u2009\u00b1\u20090.20\u00a0mm; <jats:italic>p<\/jats:italic>\u2009=\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Implantation of a magnesium-based bioresorbable stent in patients with acute coronary syndrome is associated with a greater extent of late lumen loss at the 12-month follow-up compared with implantation of a permanent, everolimus-eluting metallic stent.<\/jats:p>\n                <jats:p><jats:bold>Trial Registration:<\/jats:bold> ISRCTN89434356<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-021-07258-z","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T09:02:31Z","timestamp":1631264551000},"page":"1129-1136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-3635","authenticated-orcid":false,"given":"Petr","family":"Tou\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Lazar\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Varva\u0159ovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Nov\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Neuberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Ko\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"issue":"5","key":"7258_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","volume":"137","author":"ZA Ali","year":"2018","unstructured":"Ali ZA, Gao R, Kimura T, et al. Three-year outcomes with the Absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation. 2018;137(5):464\u201379.","journal-title":"Circulation"},{"issue":"8","key":"7258_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4244\/EIJ-D-19-01079","volume":"16","author":"PC Smits","year":"2020","unstructured":"Smits PC, Chang CC, Chevalier B, et al. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: The COMPARE-ABSORB randomised clinical trial. EuroIntervention. 2020;16(8):645\u201353.","journal-title":"EuroIntervention"},{"issue":"16","key":"7258_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.4244\/EIJ-D-19-00773","volume":"15","author":"S Brugaletta","year":"2020","unstructured":"Brugaletta S, Gori T, Tousek P, et al. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study. EuroIntervention. 2020;15(16):1436\u201343.","journal-title":"EuroIntervention"},{"issue":"1","key":"7258_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4244\/EIJV12I1A5","volume":"12","author":"P Tousek","year":"2016","unstructured":"Tousek P, Kocka V, Maly M, et al. Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update. EuroIntervention. 2016;12(1):23\u20139.","journal-title":"EuroIntervention"},{"issue":"1","key":"7258_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12967-020-02230-1","volume":"18","author":"V Kocka","year":"2020","unstructured":"Kocka V, Tousek P, Kozel M, et al. Bioresorbable scaffold implantation in STEMI patients: 5 years imaging subanalysis of PRAGUE-19 study. J Transl Med. 2020;18(1):33.","journal-title":"J Transl Med"},{"issue":"1","key":"7258_CR6","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ccd.29260","volume":"98","author":"S Verheye","year":"2021","unstructured":"Verheye S, Wlodarczak A, Montorsi P, et al. BIOSOLVE-IV-registry: safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients. Catheter Cardiovasc Interv. 2021;98(1):E1\u20138.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"9","key":"7258_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.carrev.2020.04.006","volume":"21","author":"M Haude","year":"2020","unstructured":"Haude M, Ince H, Kische S, et al. Sustained safety and performance of the second-generation sirolimus-eluting absorbable metal scaffold: pooled outcomes of the BIOSOLVE-II and -III trials at 3 years. Cardiovasc Revasc Med. 2020;21(9):1150\u20134.","journal-title":"Cardiovasc Revasc Med"},{"issue":"23","key":"7258_CR8","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.119.043467","volume":"140","author":"M Sabate","year":"2019","unstructured":"Sabate M, Alfonso F, Cequier A, et al. Magnesium-based resorbable scaffold versus permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: the MAGSTEMI Randomized Clinical Trial. Circulation. 2019;140(23):1904\u201316.","journal-title":"Circulation"},{"issue":"11","key":"7258_CR9","doi-asserted-by":"publisher","first-page":"e913","DOI":"10.4244\/EIJ-D-20-00198","volume":"16","author":"J Gomez-Lara","year":"2020","unstructured":"Gomez-Lara J, Ortega-Paz L, Brugaletta S, et al. Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. EuroIntervention. 2020;16(11):e913\u201321.","journal-title":"EuroIntervention"},{"issue":"13","key":"7258_CR10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.4244\/EIJ-D-19-00421","volume":"16","author":"L Ortega-Paz","year":"2021","unstructured":"Ortega-Paz L, Brugaletta B, Gomez-Lara J, et al. Target lesion revascularisation of bioresorbable metal scaffolds: a case series study and literature review. EuroIntervention. 2021;16(13):1100\u20133.","journal-title":"EuroIntervention"},{"issue":"4","key":"7258_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/fca-2018-0081","volume":"15","author":"E Cerrato","year":"2019","unstructured":"Cerrato E, Barbero U, Gil Romero JA, et al. Magmaris resorbable magnesium scaffold: state-of-art review. Future Cardiol. 2019;15(4):267\u201379.","journal-title":"Future Cardiol"},{"issue":"6","key":"7258_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.carrev.2016.05.001","volume":"17","author":"W Schmidt","year":"2016","unstructured":"Schmidt W, Behrens P, Brandt-Wunderlich C, et al. In vitro performance investigation of bioresorbable scaffolds - standard tests for vascular stents and beyond. Cardiovasc Revasc Med. 2016;17(6):375\u201383.","journal-title":"Cardiovasc Revasc Med"},{"issue":"2","key":"7258_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"F-J Neumann","year":"2019","unstructured":"Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87\u2013165.","journal-title":"Eur Heart J"},{"issue":"2","key":"7258_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000499536","volume":"142","author":"A Ielasi","year":"2019","unstructured":"Ielasi A, Cerrato E, Geraci S, et al. Sirolimus-eluting magnesium resorbable scaffold implantation in patients with acute myocardial infarction. Cardiology. 2019;142(2):93\u20136.","journal-title":"Cardiology"},{"issue":"5","key":"7258_CR15","doi-asserted-by":"publisher","first-page":"E287","DOI":"10.1002\/ccd.28036","volume":"93","author":"A Wlodarczak","year":"2019","unstructured":"Wlodarczak A, Lanocha M, Jastrzebski A, et al. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry. Catheter Cardiovasc Interv. 2019;93(5):E287\u201392.","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07258-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07258-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07258-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T11:06:27Z","timestamp":1668164787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07258-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7258"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07258-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"3 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the multicentre ethics committee of University Hospital Kralovske Vinohrady, Prague, Czech Republic (approval no. EK-VP\/29\/2017).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}